Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methods for a model blind proficiency testing system.

L K Hofherr1, K M Peddecord, A S Benenson

  • 1College of Health and Human Services, San Diego State University, CA 92182.

Clinical Laboratory Science : Journal of the American Society for Medical Technology
|April 8, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling the impact of a supervised consumption site on HIV and HCV transmission among people who inject drugs in three counties in California, USA.

The International journal on drug policy·2024
Same author

Evaluation of recorded video-observed therapy for anti-tuberculosis treatment.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

Prevalence and Correlates of Injecting with Visitors from the United States Among People Who Inject Drugs in Tijuana, Mexico.

Journal of immigrant and minority health·2019
Same author

Do law enforcement interactions reduce the initiation of injection drug use? An investigation in three North American settings.

Drug and alcohol dependence·2017
Same author

<i>Mycobacterium tuberculosis</i> infection among persons who inject drugs in San Diego, California.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2017
Same author

Mobility patterns of persons at risk for drug-resistant tuberculosis in Mumbai, India.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2016

A new blind proficiency testing (PT) system was developed to evaluate clinical laboratory performance for human immunodeficiency virus type 1 antibody testing. This innovative PT approach proved acceptable and advantageous over traditional external testing methods.

Area of Science:

  • Clinical Laboratory Science
  • Public Health
  • Immunology

Background:

  • Clinical laboratories require robust quality assurance systems.
  • Evaluating laboratory performance is crucial for accurate diagnostics.
  • Traditional proficiency testing (PT) methods have limitations.

Purpose of the Study:

  • To present a novel blind proficiency testing (PT) system for clinical laboratories.
  • To evaluate the performance of laboratories conducting human immunodeficiency virus type 1 antibody testing.
  • To assess the advantages of this blind PT system over conventional methods.

Main Methods:

  • Development and pilot testing of a blind PT system.
  • Incorporation of 32 laboratories and 12 counseling/testing sites.

Related Experiment Videos

  • Conducting five blind PT surveys with 306 simulated patient specimens for HIV-1 antibody testing between June 1988 and December 1989.

    • Main Results:

    • The blind PT system successfully incorporated multiple laboratories and testing sites.
    • Five surveys were completed, involving 306 proficiency specimens.
    • The system demonstrated acceptability and specific advantages compared to conventional external testing.

    Conclusions:

    • The developed blind PT system is a viable and advantageous method for assessing clinical laboratory performance.
    • This approach offers improvements over traditional external proficiency testing.
    • The system contributes to enhancing the quality of human immunodeficiency virus type 1 antibody testing.